Study Stopped
An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.
3 other identifiers
interventional
62
6 countries
68
Brief Summary
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Aug 2008
68 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 12, 2008
CompletedFirst Posted
Study publicly available on registry
June 17, 2008
CompletedStudy Start
First participant enrolled
August 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedResults Posted
Study results publicly available
January 18, 2017
CompletedJuly 11, 2018
March 1, 2018
1.6 years
June 12, 2008
March 14, 2016
June 13, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase
The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.
From Visit 4 (week 1) to the end of the Evaluation Period (week 17) (approximately 16 weeks)
Study Arms (2)
Brivaracetam (BRV) 1
EXPERIMENTAL50 mg daily
Brivaracetam (BRV) 2
EXPERIMENTAL100 mg daily
Interventions
25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
Eligibility Criteria
You may qualify if:
- Subjects from 16 to 75 years, both inclusive
- Well-characterized focal epilepsy or epileptic syndrome
- Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period
- Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50% of the minimum recommended maintenance dose
You may not qualify if:
- Seizure type IA non-motor as only seizure type
- History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline
- Other serious uncontrolled disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UCB Pharmalead
Study Sites (68)
Unknown Facility
Little Rock, Arkansas, United States
Unknown Facility
Garden Grove, California, United States
Unknown Facility
Loma Linda, California, United States
Unknown Facility
Newport Beach, California, United States
Unknown Facility
Riverside, California, United States
Unknown Facility
Sacramento, California, United States
Unknown Facility
Stanford, California, United States
Unknown Facility
Denver, Colorado, United States
Unknown Facility
Fort Collins, Colorado, United States
Unknown Facility
Danbury, Connecticut, United States
Unknown Facility
New Haven, Connecticut, United States
Unknown Facility
Waterbury, Connecticut, United States
Unknown Facility
Gainesville, Florida, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Honolulu, Hawaii, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Danville, Indiana, United States
Unknown Facility
Elkhart, Indiana, United States
Unknown Facility
Waldorf, Maryland, United States
Unknown Facility
Grand Rapids, Michigan, United States
Unknown Facility
Columbia, Missouri, United States
Unknown Facility
Lebanon, New Hampshire, United States
Unknown Facility
Albuquerque, New Mexico, United States
Unknown Facility
Flushing, New York, United States
Unknown Facility
Schenectady, New York, United States
Unknown Facility
Charlotte, North Carolina, United States
Unknown Facility
Oberlin, Ohio, United States
Unknown Facility
Westerville, Ohio, United States
Unknown Facility
Tulsa, Oklahoma, United States
Unknown Facility
Bethlehem, Pennsylvania, United States
Unknown Facility
Jenkintown, Pennsylvania, United States
Unknown Facility
Providence, Rhode Island, United States
Unknown Facility
Austin, Texas, United States
Unknown Facility
Bedford, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Layton, Utah, United States
Unknown Facility
Ogden, Utah, United States
Unknown Facility
Burlington, Vermont, United States
Unknown Facility
Bluefield, Virginia, United States
Unknown Facility
Seattle, Washington, United States
Unknown Facility
Morgantown, West Virginia, United States
Unknown Facility
Marshfield, Wisconsin, United States
Unknown Facility
Béthune, France
Unknown Facility
Lille, France
Unknown Facility
Saint-Brieuc, France
Unknown Facility
Toulouse, France
Unknown Facility
Berlin, Germany
Unknown Facility
Bernau, Germany
Unknown Facility
Bielefeld, Germany
Unknown Facility
München, Germany
Unknown Facility
Münster, Germany
Unknown Facility
Ulm, Germany
Unknown Facility
Budapest, Hungary
Unknown Facility
Debrecen, Hungary
Unknown Facility
Kecskemét, Hungary
Unknown Facility
Szeged, Hungary
Unknown Facility
Bergamo, Italy
Unknown Facility
Florence, Italy
Unknown Facility
Germaneto, Italy
Unknown Facility
Messina, Italy
Unknown Facility
Perugia, Italy
Unknown Facility
Pisa, Italy
Unknown Facility
Torino, Italy
Unknown Facility
Barcelona, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Murcia, Spain
Unknown Facility
Zaragoza, Spain
Related Publications (1)
Arnold S, Badalamenti V, Diaz A, Gasalla T, McShea C, Whitesides J, Fakhoury T. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies. Epilepsy Res. 2018 Mar;141:73-82. doi: 10.1016/j.eplepsyres.2018.02.005. Epub 2018 Feb 12.
PMID: 29486396RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- UCB (Study Director)
- Organization
- UCB Clinical Trial Call Center
Study Officials
- STUDY DIRECTOR
UCB Clinical Trial Call Center
+1 877 822 9493 (UCB)
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
- Expanded Access
- Yes
Study Record Dates
First Submitted
June 12, 2008
First Posted
June 17, 2008
Study Start
August 1, 2008
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
July 11, 2018
Results First Posted
January 18, 2017
Record last verified: 2018-03